• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Helper
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees for your businessNEW
    Legal
    Terms of usePrivacy policyCookie policy

    Windtree Therapeutics Appoints Mark Strobeck, Ph.D. to Board of Directors

    6/27/23 8:00:00 AM ET
    $WINT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $WINT alert in real time by email

    WARRINGTON, Pa., June 27, 2023 (GLOBE NEWSWIRE) -- Windtree Therapeutics, Inc. ("Windtree" or the "Company") (NasdaqCM: WINT), a biotechnology company focused on advancing late-stage interventions for cardiovascular disorders, today announced that the Company appointed Mark Strobeck, Ph.D. to its Board of Directors.

    Dr. Strobeck has more than 20 years of experience in operations, business development, capital raising and M&A and has a track record of success creating and building value for emerging and public biotechnology and life sciences companies. Currently, Dr. Strobeck is President and CEO, and a Member of the Board, at Rockwell Medical, a publicly held healthcare company that develops, manufactures, commercializes, and distributes a portfolio of hemodialysis products for dialysis providers worldwide. Prior to joining Rockwell in 2022, Dr. Strobeck was a Managing Partner at Aquilo Partners, a life science investment banking firm specializing in M&A and strategic partnering transactions. Additionally, he was COO at Zyla Lifesciences (acquired by Assertio Therapeutics), President and CEO of Corridor Pharmaceuticals (acquired by AstraZeneca), and CBO of Topaz Pharmaceuticals (acquired by Sanofi Pasteur). Dr. Strobeck also served as CBO of Trevena, and Vice President of Business Development at GSK where he was responsible for numerous transactions. Earlier in his career, he worked at two venture capital firms, SR One and EuclidSR Partners making investments in drug discovery and drug development companies. Dr. Strobeck completed a post-doctoral fellowship in cardiovascular medicine at the University of Pennsylvania, earned a Ph.D. in pharmacology and cell biophysics from the University of Cincinnati, and earned his bachelor's degree in biology from St. Lawrence University.

    Craig Fraser, Windtree's President and Chief Executive Officer said, "We are pleased to welcome Mark as a new independent director to Windtree's Board of Directors. Mark's R&D background, combined with his broad professional and deal experience, will be invaluable for Windtree as we work to advance our clinical development programs and pursue transactions that will potentially drive value for our shareholders. Mark will be highly complementary to our existing Board of Directors which includes Dan Geffkin, Leslie Williams, Dr. Rob Scott and myself, as we continue to advance therapies to treat critically-ill cardiac patients."

    "I am excited to join Craig and the Windtree team and support their strategy and vision going forward," said Dr. Strobeck. "There is a significant unmet medical need in the cardiovascular space, and I am excited by istaroxime's unique mechanism of action and pharmacological profile. Windtree's portfolio has the potential to significantly benefit patients suffering from cardiovascular disease. The Company has a number of strategic opportunities and clinical milestones ahead and I look forward to supporting Windtree to help drive value for patients and shareholders."

    About Windtree Therapeutics, Inc.

    Windtree Therapeutics, Inc. ("Windtree" or the "Company") (NasdaqCM: WINT) is advancing multiple late-stage interventions for cardiovascular disorders to treat patients in moments of crisis. Using new scientific and clinical approaches, Windtree is developing a multi-asset franchise anchored around compounds that have an ability to activate SERCA2a. The Company's lead candidate is istaroxime, a first-in-class treatment for acute heart failure and for early cardiogenic shock. Windtree's heart failure platform also includes follow-on oral pre-clinical SERCA2a activator assets. In pulmonary care, Windtree has focused on facilitating the transfer of the KL4 surfactant platform, to its licensee, Lee's Pharmaceutical (HK) Ltd. Windtree's portfolio also includes rostafuroxin, a novel precision drug product targeting hypertensive patients with certain genetic profiles.

    Forward Looking Statements

    This press release contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. The Company may, in some cases, use terms such as "predicts," "believes," "potential," "proposed," "continue," "estimates," "anticipates," "expects," "plans," "intends," "may," "could," "might," "will," "should" or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. Forward-looking statements may include, without limitation, statements regarding the Company's expectations with respect to market conditions, the timing and completion of the Offering and the intended use of net proceeds from the Offering. Such statements are based on information available to the Company as of the date of this press release and are subject to numerous important factors, risks and uncertainties that may cause actual events or results to differ materially from the Company's current expectations. Examples of such risks and uncertainties include, but are not limited to: risks and uncertainties associated with the economic and social consequences of the COVID-19 pandemic, including any adverse impact on the Company's clinical trials, clinical trial timelines or disruption in supply chain; the success and advancement of the clinical development programs for istaroxime and the Company's other product candidates; the Company's ability to secure significant additional capital as and when needed; and the Company's ability to access the debt or equity markets. These and other risks are described in the Company's periodic reports, including its Annual Report on Form 10-K, Quarterly Reports on Form 10-Q and Current Reports on Form 8-K, filed with or furnished to the Securities and Exchange Commission and available at www.sec.gov. Any forward-looking statements that the Company makes in this press release speak only as of the date of this press release. The Company assumes no obligation to update forward-looking statements whether as a result of new information, future events or otherwise, after the date of this press release.

    Contact Information:

    Monique Kosse

    LifeSci Advisors

    212.915.3820 or [email protected]



    Primary Logo

    Get the next $WINT alert in real time by email

    Crush Q3 2025 with the Best AI Executive Assistant

    Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Tailforce.ai

    Recent Analyst Ratings for
    $WINT

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $WINT
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • President and CEO Fraser Craig bought $4,942 worth of shares (5,431 units at $0.91), increasing direct ownership by 169% to 8,638 units (SEC Form 4)

      4 - WINDTREE THERAPEUTICS INC /DE/ (0000946486) (Issuer)

      10/9/24 7:46:52 AM ET
      $WINT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Fraser Craig bought $2,550 worth of shares (2,500 units at $1.02), increasing direct ownership by 5% to 57,877 units (SEC Form 4)

      4 - WINDTREE THERAPEUTICS INC /DE/ (0000946486) (Issuer)

      9/28/23 7:24:59 AM ET
      $WINT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Fraser Craig bought $2,250 worth of shares (2,500 units at $0.90), increasing direct ownership by 5% to 55,377 units (SEC Form 4)

      4 - WINDTREE THERAPEUTICS INC /DE/ (0000946486) (Issuer)

      9/27/23 7:34:59 AM ET
      $WINT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $WINT
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Windtree Announces Issuance of Istaroxime Patent for the United States for Acute Heart Failure

      1.3 million patients are hospitalized annually in the U.S. from acute heart failure and it is the #1 cause of hospitalization in patients >65 years old If istaroxime is approved in the US for acute heart failure, this patent would provide protection to 2039 WARRINGTON, Pa., July 02, 2025 (GLOBE NEWSWIRE) -- Windtree Therapeutics, Inc. ("Windtree" or the "Company") (NasdaqCM: WINT), a diversified company focused on revenue generation in multiple growing industries is pleased to announce that the United States Patent and Trademark Office has issued an istaroxime patent for the United States - application number 18/150,870 directed to "ISTAROXIME-CONTAINING INTRAVENOUS FORMULATION FOR THE T

      7/2/25 9:00:00 AM ET
      $WINT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Windtree Announces Istaroxime Phase 2 Cardiogenic Shock Study Hits Enrollment Target for Planned Interim Analysis

      The SEISMiC C Study is the third study in the istaroxime cardiogenic shock development program - SEISMiC C is studying more severely ill SCAI Stage C cardiogenic shock patients Windtree has previously reported two positive early cardiogenic shock Phase 2 studies in SCAI Stage B patients The SEISMiC C interim analysis will provide a preliminary assessment of istaroxime safety in treating more severe cardiogenic shock patients who may be receiving standard of care with inotropes and vasopressors SCAI Stage C is a sicker patient population than early cardiogenic shock and has high mortality despite currently used drug treatments WARRINGTON, Pa., June 30, 2025 (GLOBE NEWSWIRE) --

      6/30/25 9:00:00 AM ET
      $WINT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Windtree Advances Lower Cost Manufacturing of PHEXXI, Evofem's Hormone-Free, On-Demand Prescription Contraceptive Gel

      Windtree rapidly advancing lower cost PHEXXI manufacturing under March 2025 sourcing agreement Contract inked with outside U.S manufacturer to cut PHEXXI manufacturing costs by over 50% by end of 2026 Tech transfer underway with validation batch manufacturing expected to begin in 2026 Evofem and Windtree exploring other partnerships WARRINGTON, Pa., June 26, 2025 (GLOBE NEWSWIRE) -- Windtree Therapeutics, Inc. ("Windtree" or "the Company") (NASDAQ:WINT) today announced that it has contracted with a pharmaceutical manufacturer in China to produce Evofem's hormone-free contraceptive product, PHEXXI® (lactic acid, citric acid and potassium bitartrate), at a cost that is significantly bel

      6/26/25 4:05:00 PM ET
      $WINT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $WINT
    Leadership Updates

    Live Leadership Updates

    See more
    • Evofem Biosciences' CEO Saundra Pelletier Joins Aditxt Board of Directors

      Aditxt, Inc. (NASDAQ:ADTX) ("Aditxt" or the "Company"), a social innovation platform accelerating promising health innovations, today announced the appointment of Saundra Pelletier, CEO of Evofem Biosciences, Inc. (OTCPK: EVFM) ("Evofem"), to Aditxt's Board of Directors. "We believe that Saundra's background as a CEO and entrepreneur, coupled with her deep industry expertise and knowledge, will complement our current Board well. We look forward to her contributions at this critical stage as we seek to execute our growth strategy for the overall business, transition Aditxt to a commercial stage company, and advance our plans to build a vertical focus on monitoring, prevention and treatment

      6/9/25 8:15:00 AM ET
      $ADTX
      $WINT
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Biotechnology: Biological Products (No Diagnostic Substances)
    • Windtree Announces the Addition of Leanne Kelly to Its Board of Directors

      WARRINGTON, Pa., Jan. 13, 2025 (GLOBE NEWSWIRE) -- Windtree Therapeutics, Inc. ("Windtree" or the "Company") (NasdaqCM: WINT), a biotechnology company focused on advancing early and late-stage innovative therapies for critical conditions and diseases, today announced the appointment of Leanne Kelly to its board of directors ("Board"). Ms. Kelly has significant public company executive experience and joins the Board as an independent director and chair of the audit committee. Ms. Kelly has served as GRI Bio's Chief Financial Officer since April 2023. She brings over 20 years of experience leading private and publicly traded companies across life science, technology and e-Commerce sectors w

      1/13/25 8:00:00 AM ET
      $WINT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Windtree Announces Leadership Transition Plan With Industry Veterans

      WARRINGTON, Pa., Nov. 14, 2024 (GLOBE NEWSWIRE) -- Windtree Therapeutics, Inc. ("Windtree" or the "Company") (NasdaqCM: WINT), a biotechnology company focused on advancing early and late-stage innovative therapies for critical conditions and diseases, today announced that Craig Fraser plans to retire from his role as Chief Executive Officer, effective December 1, 2024, after nearly nine years of distinguished service to the Company. Mr. Fraser will remain on the Board of Directors of the Company as Chairman. The Company's Board has appointed Jed Latkin, a current director of the Company, to replace Mr. Fraser as CEO and Mr. Latkin will also remain a member of the Board. Mr. Fraser has ser

      11/14/24 8:00:00 AM ET
      $WINT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $WINT
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 3 filed by new insider Kelly Leanne

      3 - WINDTREE THERAPEUTICS INC /DE/ (0000946486) (Issuer)

      1/14/25 4:17:38 PM ET
      $WINT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • President and CEO Fraser Craig bought $4,942 worth of shares (5,431 units at $0.91), increasing direct ownership by 169% to 8,638 units (SEC Form 4)

      4 - WINDTREE THERAPEUTICS INC /DE/ (0000946486) (Issuer)

      10/9/24 7:46:52 AM ET
      $WINT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 3 filed by new insider Pelletier Saundra L

      3 - WINDTREE THERAPEUTICS INC /DE/ (0000946486) (Issuer)

      8/14/24 4:24:25 PM ET
      $WINT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $WINT
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Oppenheimer initiated coverage on Windtree Therapeutics with a new price target

      Oppenheimer initiated coverage of Windtree Therapeutics with a rating of Outperform and set a new price target of $8.00

      6/4/21 6:09:49 AM ET
      $WINT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $WINT
    SEC Filings

    See more
    • Windtree Therapeutics Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Financial Statements and Exhibits

      8-K - WINDTREE THERAPEUTICS INC /DE/ (0000946486) (Filer)

      7/3/25 2:26:36 PM ET
      $WINT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Windtree Therapeutics Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Termination of a Material Definitive Agreement, Unregistered Sales of Equity Securities, Leadership Update, Financial Statements and Exhibits

      8-K - WINDTREE THERAPEUTICS INC /DE/ (0000946486) (Filer)

      6/27/25 5:27:55 PM ET
      $WINT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Windtree Therapeutics Inc. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing

      8-K - WINDTREE THERAPEUTICS INC /DE/ (0000946486) (Filer)

      6/20/25 5:20:24 PM ET
      $WINT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $WINT
    Financials

    Live finance-specific insights

    See more
    • Windtree Therapeutics Reports First Quarter 2025 Financial Results and Provides Key Business Updates

      WARRINGTON, Pa., May 16, 2025 (GLOBE NEWSWIRE) -- Windtree Therapeutics, Inc. ("Windtree" or "the Company") (NasdaqCM: WINT), a biotechnology company focused on becoming a revenue generating company and advancing early and late-stage innovative therapies for critical conditions, today reported financial results for the first quarter ended March 31, 2025 and provided key business updates. "The first quarter of 2025 was marked with significant progress. We announced our new corporate strategy to become a revenue generating company by seeking to identify and acquire revenue-generating FDA-approved assets while advancing our cardiology and oncology pipeline," said Jed Latkin, Chief Executive

      5/16/25 8:00:00 AM ET
      $WINT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Windtree Therapeutics Reports Year-End 2024 Financial Results and Provides Key Business Updates

      WARRINGTON, Pa., April 15, 2025 (GLOBE NEWSWIRE) -- Windtree Therapeutics, Inc. ("Windtree" or "the Company") (NasdaqCM: WINT), a biotechnology company focused on advancing early and late-stage innovative therapies for critical conditions, today reported financial results for the fiscal year ended December 31, 2024 and provided key business updates. "The year 2024 saw Windtree make great progress in many key areas including clinical development of our lead drug candidate istaroxime in cardiogenic shock, business development and the future strategy of the Company," said Jed Latkin, CEO of Windtree. "Cardiogenic shock is a critical condition with high morbidity and mortality where clinician

      4/15/25 8:00:00 AM ET
      $EVFM
      $WINT
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Biotechnology: Biological Products (No Diagnostic Substances)
    • Evofem Reports Fourth Consecutive Year of Net Sales Growth

      -- 2024 Net Sales Increased 6% to $19.4 Million -- -- Total Operating Expense Reduced 27% from 2023 Levels, Excluding Non-cash Amortization Expense -- -- Sales and Marketing Expense as a Percentage of Net Sales was 47% for 2024 and 31% for the Fourth Quarter, the Most Favorable Ratios since the PHEXXI Launch -- SAN DIEGO, March 24, 2025 /PRNewswire/ -- Women's health innovator Evofem Biosciences, Inc. (OTCQB:EVFM), today announced financial results for the fourth quarter and year ended December 31, 2024. Highlights include: EVFM) (PRNewsfoto/Evofem Biosciences, Inc.)" alt="Women's health innovator Evofem Biosciences (OTCQB:E

      3/24/25 8:30:00 AM ET
      $ADTX
      $EVFM
      $WINT
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Biotechnology: Biological Products (No Diagnostic Substances)

    $WINT
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Windtree Therapeutics Inc.

      SC 13G/A - WINDTREE THERAPEUTICS INC /DE/ (0000946486) (Subject)

      11/14/24 7:15:44 PM ET
      $WINT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13G filed by Windtree Therapeutics Inc.

      SC 13G - WINDTREE THERAPEUTICS INC /DE/ (0000946486) (Subject)

      11/14/24 3:40:27 PM ET
      $WINT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Windtree Therapeutics Inc.

      SC 13G/A - WINDTREE THERAPEUTICS INC /DE/ (0000946486) (Subject)

      11/14/24 8:53:39 AM ET
      $WINT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care